CDKN1B and neoplasm: In conclusion, we provide the first evidence that among patients who develop MEN1-related tumours, those bearing the CDKN1B V109G polymorphism have a higher frequency to develop aggressive tumours and hence a more aggressive behaviour, emphasizing the added value of this variant.